BRAF and metastatic melanoma: Although the availability of three FDA-approved MAPK pathway (BRAF and MEK) inhibitors has benefited many patients with BRAF-V600E metastatic melanoma, nearly 30% of BRAF-V600E melanomas do not respond to inhibitors of the MAPK pathway [5].